Mortuaire, G., de Gabory, L., François, M., Massé, G., Bloch, F., Brion, N., ... Serrano, E. Rebound congestion and rhinitis medicamentosa: Nasal decongestants in clinical practice. (2013, June 1). Critical review of the literature by a medical panel. European Annals of Otorhinolaryngology, Head and Neck Diseases , 130(3), 137-144. Retrieved from https:///#!/content/playContent/1--S1879729612001378?returnurl=http:%2F%%2Fretrieve%2Fpii%2FS1879729612001378%3Fshowall%3Dtrue&referrer=https:%2F%2F .
In rabbits, fetal weight reduction and cleft palate were observed at a fluticasone propionate dose approximately times the MRHDID for adults (on a mg/m² basis at a maternal subcutaneous dose of 4 mcg/kg/day). However, no teratogenic effects were reported at fluticasone propionate doses up to approximately 20 times the MRHDID for adults (on a mg/m² basis at a maternal oral dose up to 300 mcg/kg/day). No fluticasone propionate was detected in the plasma in this study, consistent with the established low bioavailability following oral administration [see CLINICAL PHARMACOLOGY ].